Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Influence of sample centrifugation on plasma platelet count and activated partial thromboplastin time using patient samples

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Uncarboxylated Matrix Gla-Protein: A Biomarker of Vitamin K Status and Cardiovascular Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. Methods: SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. Results: Patients were followed for a median of 3.0 years (interquartile range 2.5– 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL −1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95% confidence interval 1.67–6.63, p = 0.001, adjusted for age) and 0.99 (0.18–5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. Conclusion: In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.

Original languageEnglish
JournalClinical Biochemistry
Pages (from-to)8-13
Number of pages6
Publication statusPublished - Jun 2020

Bibliographical note

Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Acute coronary syndrome, Biomarker, Low-grade inflammation, suPAR

ID: 59614964